FI87196B - FOR EXAMINATION OF FRAMSTAELLNING AV (Z) -1-PHENYL-1-DIETHYLAMINOCARBONYL-2-AMINOMETHYLCYCLOPROPHANE HYDROCHLORIDE - Google Patents

FOR EXAMINATION OF FRAMSTAELLNING AV (Z) -1-PHENYL-1-DIETHYLAMINOCARBONYL-2-AMINOMETHYLCYCLOPROPHANE HYDROCHLORIDE Download PDF

Info

Publication number
FI87196B
FI87196B FI861755A FI861755A FI87196B FI 87196 B FI87196 B FI 87196B FI 861755 A FI861755 A FI 861755A FI 861755 A FI861755 A FI 861755A FI 87196 B FI87196 B FI 87196B
Authority
FI
Finland
Prior art keywords
formula
process according
phenyl
carried out
reaction
Prior art date
Application number
FI861755A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI861755A (en
FI87196C (en
FI861755A0 (en
Inventor
Jean-Francois Patoiseau
Bernard Bonnaud
Henri Cousse
Gilbert Mouzin
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9318686&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI87196(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of FI861755A0 publication Critical patent/FI861755A0/en
Publication of FI861755A publication Critical patent/FI861755A/en
Publication of FI87196B publication Critical patent/FI87196B/en
Application granted granted Critical
Publication of FI87196C publication Critical patent/FI87196C/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

8719687196

Menetelmä (Z)-l-fenyyli-l-dietyyliaminokarbonyyli-2-ami-nometyylisyklopropaani hydrokloridin valmistamiseksiProcess for the preparation of (Z) -1-phenyl-1-diethylaminocarbonyl-2-aminomethylcyclopropane hydrochloride

Esillä oleva keksintö on toteutettu P.F. Medica-5 ment-tutkimuskeskuksessa ja koskee "Midalcipran"in ((Z)-l-fenyyli-l-dietyyliaminokarbonyyli-2-aminometyylisyklo-propaanin hydrokloridin yhtenäinen kansainvälinen nimitys) uutta teollista valmistusmenetelmää, jolla yhdisteellä on rakennekaava (I) 10 n ^ 0=C , ΓΗ ΓΗ 15 \ / 2 3 \ CH2CH3The present invention is embodied in P.F. Medica-5 ment and relates to a new industrial process for the preparation of "Midalcipran" in ((Z) -1-phenyl-1-diethylaminocarbonyl-2-aminomethylcyclopropane hydrochloride) with a compound of structural formula (I) 10 n ^ 0 = C, ΓΗ ΓΗ 15 \ / 2 3 \ CH2CH3

Midalcipran on tällä hetkellä kehitetty kliinisesti anti-20 depressiivisenä aineena käytettäväksi.Midalcipran is currently being developed clinically for use as an anti-20 depressant.

Aikaisemmin käytetyssä menetelmässä, joka on kuvattu patentissa FR-A-2 508 035, yhdiste on valmistettu vii-sivaiheisella menetelmällä käyttäen lähtöaineena 1-fenyy-li-2-okso-3-oksabisyklo(3:1:0)heksaania, jolloin tämä vii-. 25 meinen johdannainen on kuvattu patentissa FR-A-2 302 994.In the previously used process described in FR-A-2,508,035, the compound was prepared by a five-step process starting from 1-phenyl-2-oxo-3-oxabicyclo (3: 1: 0) hexane, whereby this -. The 25-derivative is described in patent FR-A-2 302 994.

Tunnetun tekniikan mukaisesti menetelmän rajoittava vaihe on l-fenyyli-2-aminometyylisyklopropaanihappoklori-din hydrokloridin reaktio dietyyliamiinin kanssa. Tämän reaktion aikana tapahtuu sivureaktio, nimittäin molekyy-30 linsisäinen syklisaatio, josta on seurauksena laktaamin, so. l-fenyyli-2-okso-3-atsa-bisyklo(3:1:0)heksaanin muodostuminen .According to the prior art, the limiting step of the process is the reaction of 1-phenyl-2-aminomethylcyclopropanoic acid chloride hydrochloride with diethylamine. During this reaction, a side reaction takes place, namely intramolecular cyclization, resulting in lactam, i. Formation of 1-phenyl-2-oxo-3-aza-bicyclo (3: 1: 0) hexane.

2 871962 87196

Rinnakkaisen sekundaarisen reaktion reaktioyhtälö 5 ^ H"Ee‘ o=c C1 A. J" \ /\N/Reaction equation for the parallel secondary reaction 5 ^ H "Ee 'o = c C1 A. J" \ / \ N /

Cl o ,Cl o,

HB

1010

Laktaamin eliminoinnin vuoksi on tehtävä ylimääräinen puhdistus, joka pienentää Midalcipranin saantoa.Due to lactam elimination, additional purification is required to reduce the yield of Midalcipran.

Esillä oleva keksintö koskee Midalcipranin uutta teollista valmistusmenetelmää, joka käsittää kolme syn-15 teesivaihetta. Menetelmälle on tunnusomaista, että ensim mäisestä vaiheesta lähtien muodostuu suojatussa muodossa oleva funktionaalinen amiini, joka täten sallii funktionaalisen karboksyylin aktivoinnin dietyyliamiinin konden-saatiota ajatellen ilman sekundaarisen tuotteen muodostu-20 mistä.The present invention relates to a new industrial process for the manufacture of Midalcipran comprising three synthetic steps. The process is characterized in that, from the first step, a functional amine in protected form is formed, thus allowing the activation of the functional carboxyl for the condensation of diethylamine without the formation of a secondary product.

Keksinnön mukainen menetelmä voidaan esittää seu-raavilla reaktioyhtälöillä: J 87196The process according to the invention can be represented by the following reaction equations: J 87196

Reaktiokaavio 1. vaihe /\ o / \ ftaali-imidin f 11 JV suola; liuo-Reaction Scheme Step 1 / p / imide of phthalimide f 11 JV; solvent

^ τΓ- 200-c ’ o=/v^yXJ^ τΓ- 200-c 'o = / v ^ yXJ

^OH 0 (II) (I IL) (1. vaihe tunnettu julkaisustaOH 0 (II) (IL) (1st step known from

Boll. Chim. Farm. 117 (1978), s. 331-342) 2. vaiheBoll. Chim. Farm. 117 (1978), pp. 331-342) Step 2

°/νίθ ίΗΞτ ^'Λ/yQ° / νίθ ίΗΞτ ^ 'Λ / yQ

°=\ // /'Λ OH ( f) (III) (IV) 3. vaihe o.y\.· \/ 0 0=CN Et \t \ (IV) (I) Et 4 87196° = \ // / 'Λ OH (f) (III) (IV) Step 3 o.y \. · \ / 0 0 = CN Et \ t \ (IV) (I) Et 4 87196

Menetelmän ensimmäinen vaihe käsittää kaavan II mukaisen laktonin kondensaation ftaali-imidin suolan, erikoisesti kaliumftaali-imidin kanssa, orgaanisessa liuotti-messa, joka on edullisesti valittu seuraavista: dimetyyli-5 formamidi, dimetyyliasetamidi ja metyylipyrrolidoni. Reak-tiolämpötila pidetään edullisesti 150°C:n ja 200°C:n välillä ja reaktioaika vaihtelee ollen 5-15 tuntia.The first step of the process comprises the condensation of a lactone of formula II with a phthalimide salt, especially potassium phthalimide, in an organic solvent, preferably selected from dimethyl-formamide, dimethylacetamide and methylpyrrolidone. The reaction temperature is preferably maintained between 150 ° C and 200 ° C, and the reaction time varies from 5 to 15 hours.

Toisessa reaktiovaiheessa kaava III mukainen happo käsitellään happokloridillä, erikoisesti tionyylikloridil-10 la, edullisesti käyttäen stökiömetristä ylimäärää. Reaktio toteutetaan edullisesti palautusjäähdytyksellä lämmittäen 0,5 - 2 tunnin ajan. Tionyylikloridin poistamisen jälkeen muodostunut happokloridi kondensoidaan dietyyli-amiinilla orgaanisessa liuottimessa, joka valitaan edulli-15 sesti seuraavista: metyleenikloridi, kloroformi, tetrahyd-rofuraani ja dioksaani. Tämän amidoinnin lämpötila on edullisesti alueella 5 - 30°C.In the second reaction step, the acid of formula III is treated with an acid chloride, especially thionyl chloride-10a, preferably using a stoichiometric excess. The reaction is preferably carried out under reflux with heating for 0.5 to 2 hours. The acid chloride formed after removal of the thionyl chloride is condensed with diethylamine in an organic solvent, preferably selected from methylene chloride, chloroform, tetrahydrofuran and dioxane. The temperature of this amidation is preferably in the range of 5 to 30 ° C.

Kolmannessa reaktiovaiheessa primaarinen funktionaalinen amiiniryhmä vapautetaan käsittelemällä kaavan IV 20 mukaista amidia alkyyliamiinilla tai pienen moolimassan omaavalla hydroksialkyyliamiinilla (erikoisesti etanoli-amiinilla), sellaisenaan tai liuottimen, kuten veden tai pienen molekyylipainon omaavan alkoholin (metanolin, etanolin, propanolin, isopropanolin) läsnäollessa. Tämä reak-25 tio suoritetaan ympäristön lämpötilan ja reaktioväliaineen kiehumispisteen välillä.In the third reaction step, the primary amine functional group is liberated by treating the amide of formula IV with an alkylamine or low molecular weight hydroxyalkylamine (especially ethanolamine), as such or in the presence of a solvent such as water or isol, propanol), ethanol, ethanol. This reaction is carried out between ambient temperature and the boiling point of the reaction medium.

Reaktioliuos ekstrahoidaan metyleenikloridilla, kloroformilla tai etyyliasetaatilla, ja liuottimen poistamisen jälkeen saatu jäännösöljy hydrokloorataan esim.The reaction solution is extracted with methylene chloride, chloroform or ethyl acetate, and the residual oil obtained after removal of the solvent is hydrochlorinated, e.g.

30 kloorivetyhapon etanoliliuoksen avulla, ja kaavan I mukainen yhdiste kiteytetään lisäämällä eetteriä (isopropyyli-eetteri tai formaldehydimetyylietyyliasetaali).30 with ethanolic hydrochloric acid, and the compound of formula I is crystallized by adding ether (isopropyl ether or formaldehyde methylethyl acetal).

5 871965 87196

Valmi stusohj e 1. vaihe (Z)-l-fenyyli-2-ftaali-imidimetyylisyklopropaani- 1- karboksyylihappo (yhdiste III) 5 Suspensiota, jossa on 52,56 g (0,3 mol) 1-fenyyli- 2- okso-3-oksabisyklo(3:1:0)heksaania (yhdiste II) ja 61 g (0,33 mol) kaliumftaali-imidiä 270 cm3:ssa dimetyyliform-amidia, lämmitetään 150°C:ssa samalla sekoittaen 12 tunnin ajan.Preparation Step 1 (Z) -1-Phenyl-2-phthalimidimethylcyclopropane-1-carboxylic acid (Compound III) A suspension of 52.56 g (0.3 mol) of 1-phenyl-2-oxo- 3-Oxabicyclo (3: 1: 0) hexane (compound II) and 61 g (0.33 mol) of potassium phthalimide in 270 cm 3 of dimethylformamide are heated at 150 ° C with stirring for 12 hours.

10 Liuos jäähdytetään ympäristön lämpötilaan ja lisä tään 1 000 cm3:iin vettä. Ekstrahoidaan etyyliasetaatilla, minkä jälkeen vesifaasi tehdään happameksi ylimäärällä etikkahappoa ja jäähdytetään jäissä. Kiteytynyt happo suodatetaan, pestään vedellä ja uudelleenkiteytetään etano-15 lista, jolloin saadaan 62,6 g yhdistettä III (saanto 65 %).10 Cool the solution to ambient temperature and add 1 000 cm3 of water. Extract with ethyl acetate, then acidify the aqueous phase with excess acetic acid and cool on ice. The crystallized acid is filtered, washed with water and recrystallized from ethanol-15 to give 62.6 g of compound III (yield 65%).

' ®7^<S§) C00H j 0 25'®7 ^ <S§) C00H j 0 25

Sulamispiste: 186°CMelting point: 186 ° C

Kaava: C19H15N04 : 321,22 CCM (piidioksidi - GF 254 Merck)Formula: C19H15NO4: 321.22 CCM (silica - GF 254 Merck)

Rf: 0,6 (kloroformi 85 - metanoli 15) 30 IR : (KBr) υ C=0 : 1775, 1710 ja 1650 cm'1 *H NMR (CDC13) 6 ppm (TMS) : 1,1 - 2 (m, 3H, syklopropaa-nit); 3,9 (d, 2H, CH2N); 7,15 (s, 5H, aromaattiset); 7,75 (s, 4H, aromaattiset) 35 6 87196 2. vaihe (Z )-l-fenyyli-l-dietyyliaminokarbonyyli-2-ftaali-imidometyylisyklopropaani (yhdiste IV) 30 cm3:iin tionyylikloridia lisätään vähitellen 5 sekoittaen ympäristön lämpötilassa 16,2 g (0,05 mol) 1-fenyyli-2-ftaali-imidometyylisyklopropaanikarboksyylihap-poa (yhdiste III). Ympäristön lämpötilassa saadaan 2 tunnin kuluttua homogeeninen liuos.Rf: 0.6 (chloroform 85 - methanol 15) δ IR: (KBr) υ C = 0: 1775, 1710 and 1650 cm -1 1 H NMR (CDCl 3) δ ppm (TMS): 1.1 - 2 (m , 3H, cyclopropanes); 3.9 (d, 2H, CH 2 N); 7.15 (s, 5H, aromatic); 7.75 (s, 4H, aromatic) 35 6 87196 Step 2 (Z) -1-Phenyl-1-diethylaminocarbonyl-2-phthalimidomethylcyclopropane (Compound IV) To 30 cm 3 of thionyl chloride are gradually added with stirring at ambient temperature 16, 2 g (0.05 mol) of 1-phenyl-2-phthalimidomethylcyclopropanecarboxylic acid (compound III). After 2 hours at ambient temperature a homogeneous solution is obtained.

Liuosta pidetään sitten palautusjäähdyttimessä 2 10 tuntia. Ylimääräisen tionyylikloridin poistamisen jälkeen liuos, jossa on raaka happokloridi 50 cm3:ssa metyleeni-kloridia, lisätään vähitellen liuokseen, jossa on 10,3 cm3 (0,1 mol) dietyyliamiinia ja 150 cm3 metyleenikloridia, jäähauteessa samalla sekoittaen. Yhden yön ympäristön läm-15 pötilassa tapahtuvan sekoituksen jälkeen saatu liuos pestään vedellä, kuivataan Na2S04:llä, suodatetaan ja konsentroidaan alipaineessa. Lisäämällä isopropyylieetteriä saadaan 15,4 g yhdistetä IV (saanto 82 %).The solution is then kept at reflux for 2 to 10 hours. After removal of the excess thionyl chloride, a solution of the crude acid chloride in 50 cm3 of methylene chloride is gradually added to a solution of 10.3 cm3 (0.1 mol) of diethylamine and 150 cm3 of methylene chloride in an ice bath with stirring. After stirring overnight at ambient temperature, the resulting solution is washed with water, dried over Na 2 SO 4, filtered and concentrated in vacuo. Addition of isopropyl ether gives 15.4 g of compound IV (yield 82%).

20 p. /\20 pp. / \

25 J25 J

00

Sulamispiste 131°C Kaava : C23H24N203 : 376,46 30 CCM (piidioksidi GF 254 Merck); RF : 0,66 (kloroformi 95 - metanoli 5) IR (KBr) υ C=0 1630, 1705 ja 1770 cm"1 XH NMR (CDC13) δ ppm (TMS) : 0,65 (t, 3H, CH3); 1,15 (t, 3H, CH3); 1,25 (m, 1H, syklopropaanit); 1,5 - 2,3 (m, 35 2H, syklopropaanit); 3 - 3,7 (m, 5H, CH2N, syklo-CH-N); 7 87196 4,15 (dd, 1H, syklo-CH-N); 7,1 (s, 5H, aromaattiset); 7,6 (m, 4H, aromaattiset).Melting point 131 ° C Formula: C23H24N2O3: 376.46 CCM (silica GF 254 Merck); RF: 0.66 (chloroform 95 - methanol δ) IR (KBr) δ C = 0 1630, 1705 and 1770 cm -1 1 H NMR (CDCl 3) δ ppm (TMS): 0.65 (t, 3H, CH 3); 1.15 (t, 3H, CH 3), 1.25 (m, 1H, cyclopropanes), 1.5-2.3 (m, 35 2H, cyclopropanes), 3-3.7 (m, 5H, CH 2 N, cyclo-CH-N); δ 87196 4.15 (dd, 1H, cyclo-CH-N); 7.1 (s, 5H, aromatic); 7.6 (m, 4H, aromatic).

3. vaihe (Z )-l-fenyyli-l-etyyliaminokarbonyyli-2-aminometyy-5 lisyklopropaanlhydrokloridi (yhdiste I). Midalclpran a) Suspensiota, jossa 18,82 g (0,05 mol) 1-fenyyli-l-dietyyliaminokarbonyyli-2-ftaali-imidometyylisyklopro-paania (yhdiste IV) 95 cm3:ssä metyyliamiinin 40 %:ista vesiliuosta, sekoitetaan ympäristön lämpötilassa 5 tunnin 10 ajan.Step 3 (Z) -1-Phenyl-1-ethylaminocarbonyl-2-aminomethyl-5-cyclopropane hydrochloride (Compound I). Midalclpran a) A suspension of 18.82 g (0.05 mol) of 1-phenyl-1-diethylaminocarbonyl-2-phthalimidomethylcyclopropane (Compound IV) in 95 cm 3 of a 40% aqueous solution of methylamine is stirred at ambient temperature. for 10 hours.

Tuote liuotetaan ja sitten kiteytetään Ν,Ν-dimetyy-liftaaliamidista. Suspensio ekstrahoidaan 3 kertaa etyyliasetaatilla. Orgaaninen faasi pestään vedellä, kuivataan Na2S04:llä, suodatetaan ja liuotin poistetaan alipaineessa. 15 Kloorivetyhapon etanoliliuoksen ja sitten eetterin lisäyksen jälkeen saadaan 10 g kiteistä yhdistettä I (saanto 71 %).The product is dissolved and then crystallized from Ν, Ν-dimethylphthalamide. The suspension is extracted 3 times with ethyl acetate. The organic phase is washed with water, dried over Na2SO4, filtered and the solvent is removed under reduced pressure. After addition of ethanolic hydrochloric acid solution and then ether, 10 g of crystalline compound I are obtained (yield 71%).

0../X.0 X ../.

j e,® CONEtj 25j e, ® CONEtj 25

Sulamispiste: 180°C Kaava: C15H23C1NH40H: 282,82 CCM (piidioksidi GF 245 Merck)Melting point: 180 ° C Formula: C15H23ClNH4OH: 282.82 CCM (silica GF 245 Merck)

Rf: 0,43 (kloroformi 84 - metanoli 14 - NH OH) 30 IR (KBr): υ C=0 1610 cm'1 3H NMR (D20) 6 ppm (T.S.P.) 0,8 (t, 3H, CH3); 1,15 (t, 3H, CH3); 1,5 - 2,1 (m, 3H, syklopropaanit); 3 - 3,7 (m, CH2N); 7,3 (s, aromaattiset).Rf: 0.43 (chloroform 84 - methanol 14 - NH OH) δ IR (KBr): υ C = 0 1610 cm -1 13 H NMR (D 2 O) δ ppm (T.S.P.) 0.8 (t, 3H, CH 3); 1.15 (t, 3H, CH 3); 1.5-2.1 (m, 3H, cyclopropanes); 3 - 3.7 (m, CH 2 N); 7.3 (s, aromatic).

b) Suspensiota, jossa on 60 g (0,159 mol) 1-fenyy- 35 li-l-dietyyliaminokarbonyyli-2-f taali-imidometyy li syklo- 8 87196 propaania 60 cm3:ssa etanoliamiinia, sekoitetaan 1 tunnin ajan 90°C:ssa.b) A suspension of 60 g (0.159 mol) of 1-phenyl-1-diethylaminocarbonyl-2-phthalimidomethylcyclo-8 87196 propane in 60 cm 3 of ethanolamine is stirred for 1 hour at 90 ° C. .

Lisätään 300 ml jäävettä, minkä jälkeen ekstrahoi-daan 3 kertaa etyyliasetaatilla.300 ml of ice water are added, followed by extraction 3 times with ethyl acetate.

5 Orgaaninen faasi pestään vedellä, kuivataan5 The organic phase is washed with water and dried

Na2S04:llä, suodatetaan ja liuotin poistetaan alipaineessa.Na 2 SO 4, filtered and the solvent removed under reduced pressure.

3N kloorivetyhapon etanoliliuoksen ja sitten eetterin lisäyksen jälkeen saadaan 39,7 g kiteistä yhdistettä I (saanto 88 %).After addition of 3N hydrochloric acid in ethanol and then ether, 39.7 g of crystalline compound I are obtained (yield 88%).

10 Sulamispiste: 178 - 180°C.Melting point: 178-180 ° C.

Claims (11)

1. Förfarande för industriell framställning av (Z)-l-fenyl-l-dietylaminokarbonyl-2-aminometylcyklopropan-5 hydroklorid med formeln (I) C-X/\, © © ^Vnh’ ci 10 0=C^ y CHjCHj \ CH;C!1: vid vilket förfarande 15 i) l-fenyl-2-oxo-3-oxabicyklo(3:1:0)hexan med strukturformeln (II) 0-/\ 20 f \ (II) Ay öppnas med ett sait av ftalimid i ett organiskt lösnings-25 medel, kännetecknat därav, att därefter ii) behandlas den sä erhällna (Z)-l-fenyl-2-ftal-imidometylcyklopropan-l-karboxylsyran med formeln (III): °Λγθ ““ ^OH 0 35 i3 871 96 med en syraklorid, varefter den sä bildade syrakloriden amideras genom kondensering med dietylamin i ett organiskt lösningsmedel, och lii) det sä erhällna (Z)-l-fenyl-l-dietylaminokar-5 bonyl-2-ftalimidometylcyklopropanet med strukturformeln (IV) » ^'A/vX) o c ,r.i / \c 15 behandlas med en alkylamin eller primär hydroxialkylamin som sädan eller i närvaro av ett lösningsmedel, varvid efter bildandet av hydrokloriden erhälls en förening med strukturformeln (I).1. A process for the industrial preparation of (Z) -1-phenyl-1-diethylaminocarbonyl-2-aminomethylcyclopropane hydrochloride of formula (I) C / / / V V Ci 10CHnCHjCH; C1: wherein process i) 1-phenyl-2-oxo-3-oxabicyclo (3: 1: 0) hexane of structural formula (II) O - (II) Ay is opened with a site of phthalimide in an organic solvent, characterized in that then ii) the resulting (Z) -1-phenyl-2-phthalimidomethylcyclopropane-1-carboxylic acid of formula (III) is treated with the formula (III): With the acid chloride, after which the acid chloride so formed is amidated by condensation with diethylamine in an organic solvent, and the (Z) -1-phenyl-1-diethylaminocarbonyl-2-phthalimidomethylcyclopropane of the structural formula ( IV), A / VX, and R, are treated with an alkylamine or primary hydroxyalkylamine as the seed or in the presence of a solvent, whereby after the formation of the hydrochloride a compound of structural formula (I) is obtained. 2. Förfarande enligt patentkravet 1, kanne- 20 tecknat därav, att ftalimidsaltet, som används, är kaliumftalimid.2. A process according to claim 1, characterized in that the phthalimide salt used is potassium phthalimide. 3. Förfarande enligt patentkravet 1 eller 2, k ä n-netecknat därav, att behandlingen av laktonen med formeln (II) med ftalimidsaltet utförs i ett organiskt 25 lösningsmedel, som valts bland dimetylformamid, dimetyl-acetamid och metylpyrrolidon.3. A process according to claim 1 or 2, characterized in that the treatment of the lactone of formula (II) with the phthalimide salt is carried out in an organic solvent selected from dimethylformamide, dimethylacetamide and methylpyrrolidone. 4. Förfarande enligt patentkravet 1, 2 eller 3, kännetecknat därav, att första steget vid kon-densationen av ftalimidsaltet med laktonen med formeln 30 (II) utförs vid en reaktionstemperatur, som är inom omrä-det av kokpunkten hos lösningsmedlet, som används i detta steg, företrädesvis vid 150 - 200°C.Method according to claim 1, 2 or 3, characterized in that the first step in the condensation of the phthalimide salt with the lactone of formula (II) is carried out at a reaction temperature which is within the range of the boiling point of the solvent used in this step, preferably at 150 - 200 ° C. 5. Förfarande enligt patentkravet 1, 2, 3 eller 4, kännetecknat därav, att syrakloriden, som an- 35 vänds i andra reaktiossteget, är tionylklorid. n 87196Process according to claim 1, 2, 3 or 4, characterized in that the acid chloride used in the second reaction step is thionyl chloride. n 87196 6. Förfarande enligt patentkravet 1, 2, 3, 4 eller 5, kännetecknat därav, att behandlingen av föreningen med formeln (I) med syrakloriden utförs genom uppvärming under äterloppskylning. 56. A process according to claim 1, 2, 3, 4 or 5, characterized in that the treatment of the compound of formula (I) with the acid chloride is carried out by heating under reflux. 5 7. Förfarande enligt nägot av patentkraven 1, 2, 3, 4, 5 eller 6, kännetecknat därav, att amide-ringen i andra reaktionssteget utförs i ett organiskt lös-ningsmedel, som valts bland metylenklorid, tetrahydrofuran och dioxan. 10Process according to any of claims 1, 2, 3, 4, 5 or 6, characterized in that the amidation in the second reaction step is carried out in an organic solvent selected from methylene chloride, tetrahydrofuran and dioxane. 10 8. Förfarande enligt nägot av patentkraven 1, 2, 3, 4, 5, 6 eller 7, kännetecknat därav, att reak-tionstemperaturen vid amideringen i andra steget är 5 -30°C.8. A process according to any one of claims 1, 2, 3, 4, 5, 6 or 7, characterized in that the reaction temperature during the second stage amidation is 5 -30 ° C. 9. Förfarande enligt nägot av patentkraven 1, 2, 3, 15 4, 5, 6, 7 eller 8, kännetecknat därav, att den primära aminen, som används i tredje reaktionssteget, är etanolamin.9. A process according to any one of claims 1, 2, 3, 4, 5, 6, 7 or 8, characterized in that the primary amine used in the third reaction step is ethanolamine. 10. Förfarande enligt nägot av patentkraven 1, 2, 3, 4, 5, 6, 7, 8 eller 9, kännetecknat därav, 20 att reaktionen av amiden med formeln (IV) med den primära hydroxialkylaminen utförs vid en temperatur av 60 - 100°C.10. A process according to any one of claims 1, 2, 3, 4, 5, 6, 7, 8 or 9, characterized in that the reaction of the amide of formula (IV) with the primary hydroxyalkylamine is carried out at a temperature of 60-100. ° C. 11. Förfarande enligt nägot av patentkraven 1, 2, 3, 4, 5, 6, 7, 8, 9 eller 10, kännetecknat därav, att det slutliga bildandet av hydrokloriden utförs 25 med hjälp av en etanollösning av klorvätesyra.11. A process according to any of claims 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, characterized in that the final formation of the hydrochloride is carried out by means of an ethanol solution of hydrochloric acid.
FI861755A 1985-04-25 1986-04-25 EXAMINATION OF FRAMSTAELLNING AV (Z) -1-PHENYL-1-DIETHYLAMINOCARBONYL-2-AMINOMETHYLCYCLOPROPHYL CHLORIDE FI87196C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8506335 1985-04-25
FR8506335A FR2581059B1 (en) 1985-04-25 1985-04-25 PROCESS FOR THE PREPARATION OF PHENYL-1 HYDROCHLORIDE DIETHYL AMINO CARBONYL-1 AMINOMETHYL-2 CYCLOPROPANE (Z)

Publications (4)

Publication Number Publication Date
FI861755A0 FI861755A0 (en) 1986-04-25
FI861755A FI861755A (en) 1986-10-26
FI87196B true FI87196B (en) 1992-08-31
FI87196C FI87196C (en) 1992-12-10

Family

ID=9318686

Family Applications (1)

Application Number Title Priority Date Filing Date
FI861755A FI87196C (en) 1985-04-25 1986-04-25 EXAMINATION OF FRAMSTAELLNING AV (Z) -1-PHENYL-1-DIETHYLAMINOCARBONYL-2-AMINOMETHYLCYCLOPROPHYL CHLORIDE

Country Status (23)

Country Link
EP (1) EP0200638B1 (en)
JP (1) JPS61251650A (en)
KR (1) KR940006764B1 (en)
AR (1) AR240695A1 (en)
AT (1) ATE42273T1 (en)
AU (1) AU587613B2 (en)
CA (1) CA1266486A (en)
DE (1) DE3662877D1 (en)
DK (1) DK170888B1 (en)
ES (1) ES8704449A1 (en)
FI (1) FI87196C (en)
FR (1) FR2581059B1 (en)
GE (1) GEP19970789B (en)
GR (1) GR860980B (en)
HU (1) HU195182B (en)
IE (1) IE59015B1 (en)
MX (1) MX162896B (en)
NO (1) NO165143C (en)
OA (1) OA08241A (en)
PT (1) PT82461B (en)
SU (1) SU1443797A3 (en)
YU (1) YU44915B (en)
ZA (1) ZA862929B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2640972B1 (en) * 1988-12-28 1991-04-19 Pf Medicament
US5621142A (en) * 1994-02-22 1997-04-15 Asahi Kasei Kogyo Kabushiki Kaisha Aminoalkylcyclopropane derivatives
FR2752732B1 (en) * 1996-08-28 1998-11-20 Pf Medicament EXTENDED RELEASE GALENIC FORM OF MILNACIPRAN
JP4418717B2 (en) * 2004-06-24 2010-02-24 住友化学株式会社 Process for producing (Z) -1-phenyl-1-diethylaminocarbonyl-2-aminomethylcyclopropane hydrochloride
JP4828863B2 (en) * 2005-01-28 2011-11-30 住友化学株式会社 Process for producing (Z) -1-phenyl-1- (N, N-diethylaminocarbonyl) -2-phthalimidomethylcyclopropane
WO2006132307A1 (en) 2005-06-10 2006-12-14 Pierre Fabre Medicament S.A. Stabilized milnacipran formulation
KR100772244B1 (en) * 2005-07-20 2007-11-01 안국약품 주식회사 Method for the preparation of milnacipran hydrogen chloride salt
US20090118519A1 (en) * 2006-04-17 2009-05-07 Sumitomo Chemical Company, Limited Production Method of Polycyclic Lactams
JP5338035B2 (en) * 2006-04-17 2013-11-13 住友化学株式会社 Process for producing polycyclic lactams
EP2114868A2 (en) * 2007-02-28 2009-11-11 Ranbaxy Laboratories Limited Novel polymorphic forms of milnacipran hydrochloride
FR2941454B1 (en) 2009-01-29 2011-04-01 Pf Medicament PROCESS FOR THE SYNTHESIS OF (1S, 2R) -MILNACIPRAN
US20100274050A1 (en) * 2009-04-23 2010-10-28 Glenmark Generics Limited Solid milnacipran and process for the preparation of the same
WO2012145234A2 (en) * 2011-04-21 2012-10-26 Emory University Cyclopropyl derivatives and methods of use
CN103242289B (en) * 2012-02-03 2015-01-07 暨明医药科技（苏州）有限公司 Preparation method of N,N-diallyl-(1R,2R)-2-aminomethyl-1-(2-thienyl)cyclopropanecarboxamide hydrochloride
WO2014009767A1 (en) 2012-07-07 2014-01-16 Micro Labs Limited An improved process for the preparation of 1-aryl 2-aminomethyl cyclopropane carboxyamide (z) derivatives, their isomers and salts
JP2015534464A (en) 2012-10-09 2015-12-03 カリフォルニア インスティチュート オブ テクノロジー In vivo and in vitro olefin cyclopropanation catalyzed by heme enzymes
FR2998892B1 (en) * 2012-12-04 2015-01-02 Pf Medicament AMINOCYCLOBUTANE DERIVATIVES, PROCESS FOR PREPARING THEM AND THEIR USE AS MEDICAMENTS
CN103613513B (en) * 2013-12-09 2016-01-20 上海现代制药股份有限公司 Milnacipran hydrochloride intermediate and its preparation method and application
US9399762B2 (en) 2014-02-18 2016-07-26 California Institute Of Technology Methods and systems for sulfimidation or sulfoximidation of organic molecules
CN104058992A (en) * 2014-06-13 2014-09-24 上海现代制药股份有限公司 Crystal form of levomilnacipran hydrochloride
ES2746081T3 (en) 2014-11-04 2020-03-04 Quim Sintetica S A Procedure for the preparation of (1S, 2R) -milnacipran

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2508035A1 (en) * 1981-06-23 1982-12-24 Fabre Sa Pierre ARYL-1-AMINOMETHYL-2 CYCLOPROPANES CARBOXAMIDE (Z) DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS

Also Published As

Publication number Publication date
YU44915B (en) 1991-04-30
HUT40618A (en) 1987-01-28
EP0200638A1 (en) 1986-11-05
PT82461A (en) 1986-05-01
IE59015B1 (en) 1993-12-15
NO861573L (en) 1986-10-27
PT82461B (en) 1988-10-14
IE861057L (en) 1986-10-25
DE3662877D1 (en) 1989-05-24
JPS61251650A (en) 1986-11-08
NO165143B (en) 1990-09-24
DK191286A (en) 1986-10-26
OA08241A (en) 1987-10-30
JPH0567136B2 (en) 1993-09-24
YU65586A (en) 1987-12-31
DK191286D0 (en) 1986-04-24
ZA862929B (en) 1986-12-30
CA1266486A (en) 1990-03-06
FR2581059B1 (en) 1988-04-22
DK170888B1 (en) 1996-03-04
EP0200638B1 (en) 1989-04-19
AR240695A1 (en) 1990-09-28
KR860008126A (en) 1986-11-12
ES554321A0 (en) 1987-04-01
NO165143C (en) 1991-01-09
AU5634386A (en) 1986-10-30
FI861755A (en) 1986-10-26
FI87196C (en) 1992-12-10
FI861755A0 (en) 1986-04-25
KR940006764B1 (en) 1994-07-27
ATE42273T1 (en) 1989-05-15
AU587613B2 (en) 1989-08-24
ES8704449A1 (en) 1987-04-01
SU1443797A3 (en) 1988-12-07
FR2581059A1 (en) 1986-10-31
MX162896B (en) 1991-07-08
HU195182B (en) 1988-04-28
GR860980B (en) 1986-08-25
GEP19970789B (en) 1997-01-28

Similar Documents

Publication Publication Date Title
FI87196B (en) FOR EXAMINATION OF FRAMSTAELLNING AV (Z) -1-PHENYL-1-DIETHYLAMINOCARBONYL-2-AMINOMETHYLCYCLOPROPHANE HYDROCHLORIDE
FI103889B (en) Process for the Preparation of Therapeutically Useful Pyrrolo-3,2-quinoline-Carboxylic Acid Derivatives
SU628812A3 (en) Organic compound producing method
JPH01238571A (en) Pyrrolopyridine-acetonitriles and acetamides, and use thereof as herbicide
FI70006C (en) SAOSOM MELLANPRODUKTER VID FRAMSTAELLNING AV N-ALKYLERADE 9-AMINOALKYL-9-AMINOCARBONYLFLUORENDERAT ANVAENDBARA 9-AMINOALKYL-9-AMINOCARBONYLFLUORENER
US20100152447A1 (en) Novel Method for Producing 4,4-(1-Methyl-1,2-Ethanediyl)-BIS-(2,6-Piperazinedione)
DK148232B (en) The 2-METHOXYETHYL ESTER OF 4-HYDROXY-2-METHYL-2H-1,2-BENZOTHIAZINE-3-CARBOXYLIC ACID-1,1-DIOXIDE AND PROCESS FOR THE CONVERSION OF THIS TO 4-HYDROXY-2-METHYL-N-PYL 2H-1,2-BENZOTHIAZIN-3-CARBOXAMIDE-1,1-DIOXIDE (PIROXICAM)
HU195953B (en) Process for producing occasionally substituted 2-carbamoyl-nicotinic acids, -3-quinolinecarboxylic acids and occasionally their optical isomers
FI81339C (en) FOERFARANDE FOER FRAMSTAELLNING AV PYRROLIDINODERIVAT, MELLANPRODUKT OCH DESS FRAMSTAELLNINGSFOERFARANDE.
AU744272B2 (en) Method for preparing alkyloxy furanone derivatives, compounds obtained by said method and use of said compounds
JPH059177A (en) New nitrogen-containing heterocyclic compound
CN112272665B (en) Process for preparing ritalst
US5252747A (en) Chiral quinolone intermediates
FI87770C (en) Process for the preparation of mercaptoacylproline
NO812871L (en) PROCEDURE FOR PREPARATION OF N-SUBSTITUTED N-PYRROLIDINES
CA1293509C (en) Method for the preparation of anilinofumarate
US4766218A (en) Method for the preparation of quinoline-2,3-dicarboxylic acid
DE69230730T2 (en) METHOD FOR PRODUCING BENZO [b] NAPHTHYRIDINES
FI105400B (en) Novel 3-carboxylic acid-fluoroquinoline derivatives, their preparation and their use in the preparation of benzonaphthyridine derivatives
US5290947A (en) Process for the preparation of pyrrole derivates
KR100488444B1 (en) Quinolone derivatives and a preparation method thereof
US5001254A (en) Novel method for the preparation of quinoline-2,3-dicarboxylic
DK161077B (en) METHOD OF ANALOGUE FOR THE PREPARATION OF 1,7-DIHYDROPYROLE OE3,4-EAA-OE1,4AADIAZEPIN-2 (3H) -ON DERIVATIVES OR PHARMACEUTICAL ACCEPTABLE ACID ADDITION SALTS.
FI80459C (en) NYA 3- ELLER 5- (3-PYRIDYL) SUBSTITUTE 1H, 3H-PYRROLO / 1,2-C / THIAZOLE-7-CARBOXYLSYROR, VILKA AER MELLAN PRODUKTOR
EP0180544A1 (en) Process for the preparation of a carboxylic acid

Legal Events

Date Code Title Description
SPCG Supplementary protection certificate granted

Spc suppl protection certif: L139

Extension date: 20090224

FG Patent granted

Owner name: P. F. MEDICAMENT

MA Patent expired